ANTX vs SPRO vs PRAX vs ENTA vs JPM

For growth investors, Spero Therapeutics, Inc.

(SPRO) is the stronger pick with 24. 3% revenue growth year-over-year, versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). JPMorgan Chase & Co. (JPM) offers the better valuation at 16. 0x trailing P/E (14. 4x forward), making it the more compelling value choice. Analysts rate AN2 Therapeutics, Inc. (ANTX) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, JPMorgan Chase & Co.

(JPM) is the cheapest at 16. 0x versus Spero Therapeutics, Inc. at 19. 0x. On forward P/E, Spero Therapeutics, Inc. is actually cheaper at 4. 3x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, JPMorgan Chase & Co.

(JPM) delivered a total return of +118. 2%, compared to -81. 8% for Spero Therapeutics, Inc. (SPRO). Over 10 years, the gap is even starker: JPM returned +465. 8% versus SPRO's -75. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), AN2 Therapeutics, Inc.

(ANTX) is the lower-risk stock at 0. 42β versus Praxis Precision Medicines, Inc. 's 1. 55β — meaning PRAX is approximately 268% more volatile than ANTX relative to the S&P 500. On balance sheet safety, Praxis Precision Medicines, Inc. (PRAX) carries a lower debt/equity ratio of 0% versus 3% for Enanta Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Spero Therapeutics, Inc.

(SPRO) is pulling ahead at 24. 3% versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). On earnings-per-share growth, the picture is similar: Spero Therapeutics, Inc. grew EPS 111. 8% year-over-year, compared to -32. 0% for Praxis Precision Medicines, Inc.. Over a 3-year CAGR, SPRO leads at 7. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

JPMorgan Chase & Co.

(JPM) is the more profitable company, earning 20. 4% net margin versus -125. 4% for Enanta Pharmaceuticals, Inc. — meaning it keeps 20. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JPM leads at 26. 0% versus -130. 7% for ENTA. At the gross margin level — before operating expenses — SPRO leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Spero Therapeutics, Inc.

(SPRO) trades at 4. 3x forward P/E versus 14. 4x for JPMorgan Chase & Co. — 10. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ENTA: 305. 0% to $48. 20.

In this comparison, JPM (1.

9% yield) pays a dividend. ANTX, SPRO, PRAX, ENTA do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, JPMorgan Chase & Co.

(JPM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 94), 1. 9% yield, +465. 8% 10Y return). Praxis Precision Medicines, Inc. (PRAX) carries a higher beta of 1. 55 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (JPM: +465. 8%, PRAX: -36. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (ANTX (Healthcare) and SPRO (Healthcare) and PRAX (Healthcare) and ENTA (Healthcare) and JPM (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: ANTX is a small-cap quality compounder stock; SPRO is a small-cap high-growth stock; PRAX is a small-cap quality compounder stock; ENTA is a small-cap quality compounder stock; JPM is a large-cap deep-value stock. JPM pays a dividend while ANTX, SPRO, PRAX, ENTA do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.